Beyond the Known and Established Neurodegenerative Effects: Roles of APOE Across a Wide Spectrum of Pathophysiological Condition

Abstract

Apolipoprotein E (ApoE) is classically recognized for its role in lipid trafficking and the coordination of lipoprotein metabolism, yet its influence extends well beyond these pathways. While the contribution of ApoE isoforms to neurodegenerative disorders, most notably Alzheimer's disease, has been described in considerable detail, their impact on peripheral physiology is far less clearly defined. Evidence accumulated over the past decade suggests that variation in ApoE may shape traits such as adiposity, fat and lean mass distribution, bone density, muscle function, and cardiovascular risk, although the findings are often inconsistent across studies and populations. This review brings together current knowledge on how ApoE interfaces with several key biological processes, including inflammatory signaling, glucose and insulin responses, mitochondrial and redox homeostasis, senescence, and regulated cell death. These pathways lie at the core of many chronic disorders, yet their links to ApoE genotype remain insufficiently defined. Moreover, translation of these findings, including the use of ApoE genotyping for risk stratification, therapeutic choices, and personalized prevention is also discussed. By reframing ApoE as a systemic regulator rather than a brain-restricted factor, this review offers a cohesive roadmap for interdisciplinary research and improved clinical interpretability of ApoE-associated risk.

Keywords

apolipoprotein E / bone mineral density / cardiovascular system / hepatic system / muscle mass / obesity

References

[1] V. Shore and B. Shore, “Heterogeneity of human Plasma Very Low Density Lipoproteins. Separation of Species Differing in Protein Components,” Biochemistry 12, no. 3 (1973): 502–507.

[2] G. Utermann, “Isolation and Partial Characterization of an Arginine-rich Apolipoprotein From human Plasma Very-low-density Lipoproteins: Apolipoprotein E,” Hoppe Seylers Z Physiol Chem 356, no. 7 (1975): 1113–1121.

[3] P. Huebbe and G. Rimbach, “Evolution of human Apolipoprotein E (APOE) Isoforms: Gene Structure, Protein Function and Interaction With Dietary Factors,” Ageing Research Reviews 37 (2017): 146–161.

[4] A. Raulin, S. V. Doss, Z. A. Trottier, T. C. Ikezu, G. Bu, and C. Liu, “ApoE in Alzheimer's Disease: Pathophysiology and Therapeutic Strategies,” Mol Neurodegener 17, no. 1 (2022): 72.

[5] J. K. Boyles, R. E. Pitas, E. Wilson, R. W. Mahley, and J. M. Taylor, “Apolipoprotein E Associated With Astrocytic Glia of the central Nervous System and With Nonmyelinating Glia of the Peripheral Nervous System,” Journal of Clinical Investigation 76, no. 4 (1985): 1501–1513.

[6] Q. Xu, A. Bernardo, D. Walker, T. Kanegawa, R. W. Mahley, and Y. Huang, “Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice With Targeting of Green Fluorescent Protein Gene to the ApoE Locus,” Journal of Neuroscience 26, no. 19 (2006): 4985–4994.

[7] K. Aoki, T. Uchihara, N. Sanjo, et al., “Increased Expression of Neuronal Apolipoprotein E in human Brain With Cerebral Infarction,” Stroke; A Journal of Cerebral Circulation 34, no. 4 (2003): 875–880.

[8] R. Mahley and Y. Huang, “Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology,” Neuron 76, no. 5 (2012): 871–885.

[9] A. Grubman, G. Chew, J. F. Ouyang, et al., “A Single-cell Atlas of Entorhinal Cortex From Individuals With Alzheimer's Disease Reveals Cell-type-specific Gene Expression Regulation,” Nature Neuroscience 22, no. 12 (2019): 2087–2097.

[10] M. Kockx, M. Traini, and L. Kritharides, “Cell-specific Production, Secretion, and Function of Apolipoprotein E,” J Mol Med (Berl) 96, no. 5 (2018): 361–371.

[11] L. G. Yang, Z. M. March, R. A. Stephenson, and P. S. Narayan, “Apolipoprotein E in Lipid Metabolism and Neurodegenerative Disease,” Trends in Endocrinology and Metabolism 34, no. 8 (2023): 430–445.

[12] G. Getz and C. Reardon, “Apoprotein E and Reverse Cholesterol Transport,” Int J Mol Sci 19, no. 11 (2018): 3479.

[13] G. Miao, D. Zhuo, X. Han, et al., “From Degenerative Disease to Malignant Tumors: Insight to the Function of ApoE,” Biomedicine & Pharmacotherapy 158 (2023): 114127.

[14] H. K. Das, J. McPherson, G. A. Bruns, S. K. Karathanasis, and J. L. Breslow, “Isolation, Characterization, and Mapping to Chromosome 19 of the human Apolipoprotein E Gene,” Journal of Biological Chemistry 260, no. 10 (1985): 6240–6247.

[15] B. R. Troutwine, L. Hamid, C. R. Lysaker, T. A. Strope, and H. M. Wilkins, “Apolipoprotein E and Alzheimer's Disease,” Acta Pharm Sin B 12, no. 2 (2022): 496–510.

[16] J. Alagarsamy, A. Jaeschke, and D. Hui, “Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases,” International Journal of Molecular Sciences 23, no. 17 (2022): 9892.

[17] L. Zhong, Y. Xie, T. Cao, et al., “A Rapid and Cost-effective Method for Genotyping Apolipoprotein E Gene Polymorphism,” Molecular Neurodegeneration 11, no. 1 (2016): 2.

[18] C. Hanlon, “Arginine Residues at Codons 112 and 158 in the Apolipoprotein E Gene Correspond to the Ancestral state in Humans,” Atherosclerosis 112, no. 1 (1995): 85–90.

[19] A. M. McIntosh, C. Bennett, D. Dickson, et al., “The Apolipoprotein E (APOE) Gene Appears Functionally Monomorphic in Chimpanzees (Pan troglodytes),” PLoS ONE 7, no. 10 (2012): e47760.

[20] S. M. Fullerton, A. G. Clark, K. M. Weiss, et al., “Apolipoprotein E Variation at the Sequence Haplotype Level: Implications for the Origin and Maintenance of a Major human Polymorphism,” American Journal of Human Genetics 67, no. 4 (2000): 881–900.

[21] R. Corbo and R. Scacchi, “Apolipoprotein E (APOE) Allele Distribution in the World. Is APOE*4 a ‘Thrifty’ allele?,” Annals of Human Genetics 63, no. Pt 4 (1999): 301–310.

[22] S. Egert, G. Rimbach, and P. Huebbe, “ApoE Genotype: From Geographic Distribution to Function and Responsiveness to Dietary Factors,” Proceedings of the Nutrition Society 71, no. 3 (2012): 410–424.

[23] A. Bonaterra-Pastra, S. Fernández-de-Retana, A. Rivas-Urbina, et al., “Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer's Disease,” Biomedicines 9, no. 1 (2021): 72.

[24] M. Croyal, V. Blanchard, K. Ouguerram, et al., “VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly,” Arteriosclerosis, Thrombosis, and Vascular Biology 40, no. 3 (2020): 819–829.

[25] Y. Huang and R. Mahley, “Apolipoprotein E: Structure and Function in Lipid Metabolism, Neurobiology, and Alzheimer's Diseases,” Neurobiology of Disease 72, no. Pt A (2014): 3–12.

[26] U. Beisiegel, W. Weber, G. Ihrke, J. Herz, and K. K. Stanley, “The LDL-receptor-related Protein, LRP, Is an Apolipoprotein E-binding Protein,” Nature 341, no. 6238 (1989): 162–164.

[27] V. I. Zannis, A. Chroni, K. E. Kypreos, et al., “Probing the Pathways of Chylomicron and HDL Metabolism Using adenovirus-mediated Gene Transfer,” Current Opinion in Lipidology 15, no. 2 (2004): 151–166.

[28] Z. Huang, C. Reardon, and T. Mazzone, “Endogenous ApoE Expression Modulates Adipocyte Triglyceride Content and Turnover,” Diabetes 55, no. 12 (2006): 3394–3402.

[29] C. Frieden and K. Garai, “Structural Differences Between apoE3 and apoE4 May be Useful in Developing Therapeutic Agents for Alzheimer's Disease,” Pnas USA 109, no. 23 (2012): 8913–8918.

[30] R. Mahley and S. Rall, “Apolipoprotein E: Far More Than a Lipid Transport Protein,” Annual Review of Genomics and Human Genetics 1 (2000): 507–537.

[31] R. Mahley, K. Weisgraber, and Y. Huang, “Apolipoprotein E: Structure Determines Function, From Atherosclerosis to Alzheimer's Disease to AIDS,” Journal of Lipid Research 50, no. 1 (2009): S183–S188.

[32] I. Barroeta-Espar, L. D. Weinstock, B. G. Perez-Nievas, et al., “Distinct Cytokine Profiles in human Brains Resilient to Alzheimer's Pathology,” Neurobiology of Disease 121 (2019): 327–337.

[33] F. Heppner, R. Ransohoff, and B. Becher, “Immune Attack: The Role of Inflammation in Alzheimer Disease,” Nature Reviews Neuroscience 16, no. 6 (2015): 358–372.

[34] L. Guo, M. LaDu, and L. Van Eldik, “A Dual Role for Apolipoprotein E in Neuroinflammation: Anti- and Pro-inflammatory Activity,” Journal of Molecular Neuroscience 23, no. 3 (2004): 205–212.

[35] R. D. Bell, E. A. Winkler, I. Singh, et al., “Apolipoprotein E Controls Cerebrovascular Integrity via Cyclophilin A,” Nature 485, no. 7399 (2012): 512–516.

[36] M. Hüttenrauch, I. Ogorek, H. Klafki, et al., “Glycoprotein NMB: A Novel Alzheimer's Disease Associated Marker Expressed in a Subset of Activated Microglia,” Acta Neuropathol Commun 6, no. 1 (2018): 108.

[37] K. A. Walker, L. M. Le Page, N. Terrando, M. R. Duggan, M. T. Heneka, and B. M. Bettcher, “The Role of Peripheral Inflammatory Insults in Alzheimer's Disease: A Review and Research Roadmap,” Mol Neurodegener 18, no. 1 (2023): 37.

[38] L. K. Wareham, S. A. Liddelow, S. Temple, et al., “Solving Neurodegeneration: Common Mechanisms and Strategies for New Treatments,” Mol Neurodegener 17, no. 1 (2022): 23.

[39] R. Guerreiro, A. Wojtas, J. Bras, et al., “TREM2 variants in Alzheimer's Disease,” New England Journal of Medicine 368, no. 2 (2013): 117–127.

[40] P. Hollingworth, D. Harold, R. Sims, et al., “Common Variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP Are Associated With Alzheimer's Disease,” Nature Genetics 43, no. 5 (2011): 429–435.

[41] J. Lambert, S. Heath, G. Even, et al., “Genome-wide Association Study Identifies Variants at CLU and CR1 Associated With Alzheimer's Disease,” Nature Genetics 41, no. 10 (2009): 1094–1099.

[42] Y. Atagi, C. Liu, M. M. Painter, et al., “Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2),” Journal of Biological Chemistry 290, no. 43 (2015): 26043–26050.

[43] R. Li, Q. Qin, H. Yang, et al., “TREM2 in the Pathogenesis of AD: A Lipid Metabolism Regulator and Potential Metabolic Therapeutic Target,” Mol Neurodegener 17, no. 1 (2022): 40.

[44] N. Wang, M. Wang, S. Jeevaratnam, et al., “Opposing Effects of apoE2 and apoE4 on Microglial Activation and Lipid Metabolism in Response to Demyelination,” Mol Neurodegener 17, no. 1 (2022): 75.

[45] M. F. Lanfranco, J. Sepulveda, G. Kopetsky, and G. W. Rebeck, “Expression and Secretion of apoE Isoforms in Astrocytes and Microglia During Inflammation,” Glia 69, no. 6 (2021): 1478–1493.

[46] G. Chen, Y. Zhang, S. Yu, W. Sun, and D. Miao, “Bmi1 Overexpression in Mesenchymal Stem Cells Exerts Antiaging and Antiosteoporosis Effects by Inactivating p16/p19 Signaling and Inhibiting Oxidative Stress,” Stem Cells 37, no. 9 (2019): 1200–1211.

[47] H. Zhang, L. Wu, and J. Wu, “Cross-talk Between Apolipoprotein E and Cytokines,” Mediators of Inflammation 2011 (2011): 949072.

[48] L. M. Tai, S. Ghura, K. P. Koster, et al., “APOE-modulated Aβ-induced Neuroinflammation in Alzheimer's Disease: Current Landscape, Novel Data, and Future Perspective,” Journal of Neurochemistry 133, no. 4 (2015): 465–488.

[49] Y. Zhu, E. Nwabuisi-Heath, S. B. Dumanis, et al., “APOE Genotype Alters Glial Activation and Loss of Synaptic Markers in Mice,” Glia 60, no. 4 (2012): 559–569.

[50] L. Jofre-Monseny, A. Loboda, A. E. Wagner, et al., “Effects of apoE Genotype on Macrophage Inflammation and Heme Oxygenase-1 Expression,” Biochemical and Biophysical Research Communications 357, no. 1 (2007): 319–324.

[51] D. Baitsch, H. H. Bock, T. Engel, et al., “Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology 31, no. 5 (2011): 1160–1168.

[52] A. Pocivavsek and G. Rebeck, “Inhibition of c-Jun N-terminal Kinase Increases apoE Expression in Vitro and in Vivo,” Biochemical and Biophysical Research Communications 387, no. 3 (2009): 516–520.

[53] X. Cheng, Y. Zheng, P. Bu, et al., “Apolipoprotein E as a Novel Therapeutic Neuroprotection Target After Traumatic Spinal Cord Injury,” Experimental Neurology 299, no. Pt A (2018): 97–108.

[54] E. Dorey, M. Bamji-Mirza, D. Najem, et al., “Apolipoprotein E Isoforms Differentially Regulate Alzheimer's Disease and Amyloid-β-Induced Inflammatory Response in Vivo and in Vitro,” Journal of Alzheimer's Disease 57, no. 4 (2017): 1265–1279.

[55] M. L. James, J. M. Komisarow, H. Wang, and D. T. Laskowitz, “Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury,” Neurotherapeutics 17, no. 2 (2020): 475–483.

[56] L. Wang, H. Hou, D. Zi, A. Habib, J. Tan, and D. Sawmiller, “Novel apoE Receptor Mimetics Reduce LPS-induced Microglial Inflammation,” American journal of translational research 11, no. 8 (2019): 5076–5085.

[57] C. Yin, S. Ackermann, Z. Ma, et al., “ApoE Attenuates Unresolvable Inflammation by Complex Formation With Activated C1q,” Nature Medicine 25, no. 3 (2019): 496–506.

[58] P. M. Sullivan, H. Mezdour, Y. Aratani, et al., “Targeted Replacement of the Mouse Apolipoprotein E Gene With the Common human APOE3 Allele Enhances Diet-induced Hypercholesterolemia and Atherosclerosis,” Journal of Biological Chemistry 272, no. 29 (1997): 17972–17980.

[59] G. A. Rodriguez, L. M. Tai, M. J. LaDu, and G. W. Rebeck, “Human APOE4 Increases Microglia Reactivity at Aβ Plaques in a Mouse Model of Aβ Deposition,” J Neuroinflammation 11 (2014): 111.

[60] E. B. Button, J. Robert, T. M. Caffrey, J. Fan, W. Zhao, and C. L. Wellington, “HDL From an Alzheimer's Disease Perspective,” Current Opinion in Lipidology 30, no. 3 (2019): 224–234.

[61] I. Maezawa, N. Maeda, T. J. Montine, and K. S. Montine, “Apolipoprotein E-specific Innate Immune Response in Astrocytes From Targeted Replacement Mice,” J Neuroinflammation 3 (2006): 10.

[62] G. Ophir, N. Amariglio, J. Jacob-Hirsch, R. Elkon, G. Rechavi, and D. M. Michaelson, “Apolipoprotein E4 Enhances Brain Inflammation by Modulation of the NF-kappaB Signaling Cascade,” Neurobiology of Disease 20, no. 3 (2005): 709–718.

[63] D. Dove, M. Linton, and S. Fazio, “ApoE-mediated Cholesterol Efflux From Macrophages: Separation of Autocrine and Paracrine Effects,” American Journal of Physiology. Cell Physiology 288, no. 3 (2005): C586–C592.

[64] I. Zanotti, M. Pedrelli, F. Potì, et al., “Macrophage, but Not Systemic, Apolipoprotein E Is Necessary for Macrophage Reverse Cholesterol Transport in Vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology 31, no. 1 (2011): 74–80.

[65] Y. Zhu, S. Bellosta, C. Langer, et al., “Low-dose Expression of a human Apolipoprotein E Transgene in Macrophages Restores Cholesterol Efflux Capacity of Apolipoprotein E-deficient Mouse Plasma,” PNAS 95, no. 13 (1998): 7585–7590.

[66] Y. Liu, X. Xu, H. Dou, Y. Hua, J. Xu, and X. Hui, “Apolipoprotein E Knockout Induced Inflammatory Responses Related to Microglia in Neonatal Mice Brain via Astrocytes,” International journal of clinical and experimental medicine 8, no. 1 (2015): 737–743.

[67] B. Chen, J. Yi, Y. Xu, et al., “Apolipoprotein E Knockout May Affect Cognitive Function in D-galactose-induced Aging Mice Through the Gut Microbiota-brain Axis,” Frontiers in neuroscience 16 (2022): 939915.

[68] M. I. Abeer, A. Abdulhasan, Z. Haguar, and V. Narayanaswami, “Isoform-specific Modification of Apolipoprotein E by 4-hydroxynonenal: Protective Role of Apolipoprotein E3 Against Oxidative Species,” Febs Journal 290, no. 11 (2023): 3006–3025.

[69] M. Evola, A. Hall, T. Wall, A. Young, and P. Grammas, “Oxidative Stress Impairs Learning and Memory in apoE Knockout Mice,” Pharmacology Biochemistry and Behavior 96, no. 2 (2010): 181–186.

[70] C. M. Lauderback, J. Kanski, J. M. Hackett, N. Maeda, M. S. Kindy, and D. Butterfield, “Apolipoprotein E Modulates Alzheimer's Abeta(1-42)-induced Oxidative Damage to Synaptosomes in an Allele-specific Manner,” Brain Research 924, no. 1 (2002): 90–97.

[71] C. Lin, H. Duan, and T. Mazzone, “Apolipoprotein E-dependent Cholesterol Efflux From Macrophages: Kinetic Study and Divergent Mechanisms for Endogenous versus Exogenous Apolipoprotein E,” Journal of Lipid Research 40, no. 9 (1999): 1618–1627.

[72] B. Liu, L. Fang, P. Mo, et al., “Apoe-knockout Induces Strong Vascular Oxidative Stress and Significant Changes in the Gene Expression Profile Related to the Pathways Implicated in Redox, Inflammation, and Endothelial Function,” Cell Signalling 108 (2023): 110696.

[73] W. H. Robb, O. A. Khan, H. A. Ahmed, et al., “Lower Cerebral Oxygen Utilization Is Associated With Alzheimer's Disease-related Neurodegeneration and Poorer Cognitive Performance Among Apolipoprotein E ε4 Carriers,” Journal of Cerebral Blood Flow and Metabolism 42, no. 4 (2022): 642–655.

[74] L. Caberlotto, L. Marchetti, M. Lauria, M. Scotti, and S. Parolo, “Integration of Transcriptomic and Genomic Data Suggests Candidate Mechanisms for APOE4-mediated Pathogenic Action in Alzheimer's Disease,” Scientific Reports 6 (2016): 32583.

[75] L. Shi, X. Du, H. Zhou, et al., “Cumulative Effects of the ApoE Genotype and Gender on the Synaptic Proteome and Oxidative Stress in the Mouse Brain,” International Journal of Neuropsychopharmacology 17, no. 11 (2014): 1863–1879.

[76] S. Wang, B. Li, V. Solomon, et al., “Calcium-dependent Cytosolic Phospholipase A(2) Activation Is Implicated in Neuroinflammation and Oxidative Stress Associated With ApoE4,” Mol Neurodegener 17, no. 1 (2022): 42.

[77] J. Dose, A. Nebel, S. Piegholdt, G. Rimbach, and P. Huebbe, “Influence of the APOE Genotype on Hepatic Stress Response: Studies in APOE Targeted Replacement Mice and human Liver Cells,” Free Radic Biol Med 96 (2016): 264–272.

[78] E. Schmukler, S. Solomon, S. Simonovitch, et al., “Altered Mitochondrial Dynamics and Function in APOE4-expressing Astrocytes,” Cell death & disease 11, no. 7 (2020): 578.

[79] G. Qi, Y. Mi, X. Shi, H. Gu, R. D. Brinton, and F. Yin, “ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism,” Cell reports 34, no. 1 (2021): 108572.

[80] D. Chin, S. Hagl, A. Hoehn, et al., “Adenosine Triphosphate Concentrations Are Higher in the Brain of APOE3- compared to APOE4-targeted Replacement Mice and Can be Modulated by Curcumin,” Genes Nutr 9, no. 3 (2014): 397.

[81] J. Yin, M. Nielsen, T. Carcione, S. Li, and J. Shi, “Apolipoprotein E Regulates Mitochondrial Function Through the PGC-1α-sirtuin 3 Pathway,” Aging (Albany NY) 11, no. 23 (2019): 11148–11156.

[82] J. Yin, E. M. Reiman, T. G. Beach, et al., “Effect of ApoE Isoforms on Mitochondria in Alzheimer Disease,” Neurology 94, no. 23 (2020): e2404–e2411.

[83] F. M. Marottoli, T. N. Trevino, X. Geng, et al., “Autocrine Effects of Brain Endothelial Cell-Produced Human Apolipoprotein E on Metabolism and Inflammation in Vitro,” Frontiers in Cell and Developmental Biology 9 (2021): 668296.

[84] A. L. Orr, C. Kim, D. Jimenez-Morales, et al., “Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function,” Journal of Alzheimer's Disease 68, no. 3 (2019): 991–1011.

[85] H. Sohn, S. Kim, J. Park, et al., “ApoE4 attenuates Autophagy via FoxO3a Repression in the Brain,” Scientific Reports 11, no. 1 (2021): 17604.

[86] S. Chang, T. R. Ma, R. D. Miranda, M. E. Balestra, R. W. Mahley, and Y. Huang, “Lipid- and Receptor-binding Regions of Apolipoprotein E4 Fragments Act in Concert to Cause Mitochondrial Dysfunction and Neurotoxicity,” PNAS 102, no. 51 (2005): 18694–18699.

[87] H. Chen, Z. Ji, S. E. Dodson, et al., “Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease,” Journal of Biological Chemistry 286, no. 7 (2011): 5215–5221.

[88] B. R. Troutwine, T. A. Strope, E. Franczak, et al., “Mitochondrial Function and Aβ in Alzheimer's Disease Postmortem Brain,” Neurobiology of Disease 171 (2022): 105781.

[89] J. Rueter, G. Rimbach, and P. Huebbe, “Functional Diversity of Apolipoprotein E: From Subcellular Localization to Mitochondrial Function,” Cellular and Molecular Life Sciences 79, no. 9 (2022): 499.

[90] S. Simonovitch, E. Schmukler, E. Masliah, R. Pinkas-Kramarski, and D. M. Michaelson, “The Effects of APOE4 on Mitochondrial Dynamics and Proteins in Vivo,” Journal of Alzheimer's Disease 70, no. 3 (2019): 861–875.

[91] T. Liang, W. Hang, J. Chen, et al., “ApoE4 (Δ272-299) induces Mitochondrial-associated Membrane Formation and Mitochondrial Impairment by Enhancing GRP75-modulated Mitochondrial Calcium Overload in Neuron,” Cell Biosci 11, no. 1 (2021): 50.

[92] M. Abyadeh, V. Gupta, J. A. Paulo, et al., “Apolipoprotein ε in Brain and Retinal Neurodegenerative Diseases,” Aging Dis 14, no. 4 (2023): 1311–1330.

[93] Z. Chen and C. Zhong, “Decoding Alzheimer's Disease From Perturbed Cerebral Glucose Metabolism: Implications for Diagnostic and Therapeutic Strategies,” Progress in Neurobiology 108 (2013): 21–43.

[94] R. Ossenkoppele, W. M. van der Flier, M. D. Zwan, et al., “Differential Effect of APOE Genotype on Amyloid Load and Glucose Metabolism in AD Dementia,” Neurology 80, no. 4 (2013): 359–365.

[95] L. Wu, X. Zhang, and L. Zhao, “Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention,” Journal of Neuroscience 38, no. 30 (2018): 6665–6681.

[96] J. Keeney, S. Ibrahimi, and L. Zhao, “Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention,” Journal of Alzheimer's Disease 48, no. 2 (2015): 411–424.

[97] Y. Yamazaki, N. Zhao, T. R. Caulfield, C. Liu, and G. Bu, “Apolipoprotein E and Alzheimer Disease: Pathobiology and Targeting Strategies,” Nature reviews Neurology 15, no. 9 (2019): 501–518.

[98] W. Jagust and S. Landau, “Apolipoprotein E, Not Fibrillar β-amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging,” Journal of Neuroscience 32, no. 50 (2012): 18227–18233.

[99] M. Venzi, M. Tóth, J. Häggkvist, et al., “Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [(18)F]FDG-µPET Study,” J Alzheimers Dis Rep 1, no. 1 (2017): 169–180.

[100] H. Lee, S. Cho, M. Kim, et al., “ApoE4-dependent Lysosomal Cholesterol Accumulation Impairs Mitochondrial Homeostasis and Oxidative Phosphorylation in human Astrocytes,” Cell reports 42, no. 10 (2023): 113183.

[101] B. C. Farmer, H. C. Williams, N. A. Devanney, et al., “APOΕ4 lowers Energy Expenditure in Females and Impairs Glucose Oxidation by Increasing Flux Through Aerobic Glycolysis,” Mol Neurodegener 16, no. 1 (2021): 62.

[102] X. Yan, Y. Hu, B. Wang, S. Wang, and X. Zhang, “Metabolic Dysregulation Contributes to the Progression of Alzheimer's Disease,” Frontiers in neuroscience 14 (2020): 530219.

[103] H. C. Williams, B. C. Farmer, M. A. Piron, et al., “APOE Alters Glucose Flux Through central Carbon Pathways in Astrocytes,” Neurobiology of Disease 136 (2020): 104742.

[104] J. D. Roback, E. A. Tyburski, D. Alter, et al., “The Need for New Test Verification and Regulatory Support for Innovative Diagnostics,” Nature Biotechnology 39, no. 9 (2021): 1060–1062.

[105] S. Hoyer, “Glucose Metabolism and Insulin Receptor Signal Transduction in Alzheimer disease,” European Journal of Pharmacology 490, no. 1-3 (2004): 115–125.

[106] E. Steen, B. M. Terry, E. J. Rivera, et al., “Impaired Insulin and Insulin-Like Growth Factor Expression and Signaling Mechanisms in Alzheimer's disease–is This Type 3 Diabetes?,” Journal of Alzheimer's Disease 7, no. 1 (2005): 63–80.

[107] N. Zhao, C. Liu, A. J. Van Ingelgom, et al., “Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes,” Neuron 96, no. 1 (2017): 115–129, e5.

[108] Q. Ong, E. S. Chan, M. Lim, G. M. Cole, and B. Wong, “Reduced Phosphorylation of Brain Insulin Receptor Substrate and Akt Proteins in Apolipoprotein-E4 Targeted Replacement Mice,” Scientific Reports 4 (2014): 3754.

[109] J. Gao, H. Katagiri, Y. Ishigaki, et al., “Involvement of Apolipoprotein E in Excess Fat Accumulation and Insulin Resistance,” Diabetes 56, no. 1 (2007): 24–33.

[110] M. Huang, J. Zheng, L. Chen, S. You, and H. Huang, “Role of Apolipoproteins in the Pathogenesis of Obesity,” Clinica Chimica Acta 545 (2023): 117359.

[111] B. He, Q. Nie, F. Wang, et al., “Hyperuricemia Promotes the Progression of Atherosclerosis by Activating Endothelial Cell Pyroptosis via the ROS/NLRP3 Pathway,” Journal of Cellular Physiology 238, no. 8 (2023): 1808–1822.

[112] M. A. Alam, M. Caocci, M. Ren, et al., “Deficiency of Caspase-1 Attenuates HIV-1-Associated Atherogenesis in Mice,” International Journal of Molecular Sciences 24, no. 16 (2023): 12871.

[113] Y. Zhang, Z. Cheng, L. Hong, et al., “Apolipoprotein E (ApoE) Orchestrates Adipose Tissue Inflammation and Metabolic Disorders Through NLRP3 Inflammasome,” Mol Biomed 4, no. 1 (2023): 47.

[114] A. J. Hanson, W. A. Banks, H. Hernandez Saucedo, and S. Craft, “Apolipoprotein E Genotype and Sex Influence Glucose Tolerance in Older Adults: A Cross-Sectional Study,” Dement Geriatr Cogn Dis Extra 6, no. 1 (2016): 78–89.

[115] A. Christensen and C. Pike, “Effects of APOE Genotype and Western Diet on Metabolic Phenotypes in Female Mice,” Metabolites 13, no. 2 (2023): 287.

[116] D. Chen, J. K. Shi, Y. Li, Y. Yang, and S. P. Ren, “Association Between ApoE Polymorphism and Type 2 Diabetes: A Meta-Analysis of 59 Studies,” Biomedical and Environmental Sciences 32, no. 11 (2019): 823–838.

[117] M. Croyal, M. Wargny, K. Chemello, et al., “Plasma Apolipoprotein Concentrations and Incident Diabetes in Subjects With Prediabetes,” Cardiovasc Diabetol 21, no. 1 (2022): 21.

[118] K. Bach-Ngohou, K. Ouguerram, H. Nazih, et al., “Apolipoprotein E Kinetics: Influence of Insulin Resistance and Type 2 Diabetes,” International Journal of Obesity and Related Metabolic Disorders 26, no. 11 (2002): 1451–1458.

[119] R. Chaudhary, A. Likidlilid, T. Peerapatdit, et al., “Apolipoprotein E Gene Polymorphism: Effects on Plasma Lipids and Risk of Type 2 Diabetes and Coronary Artery Disease,” Cardiovasc Diabetol 11 (2012): 36.

[120] P. Anthopoulos, S. Hamodrakas, and P. Bagos, “Apolipoprotein E Polymorphisms and Type 2 Diabetes: A Meta-analysis of 30 Studies Including 5423 Cases and 8197 Controls,” Molecular Genetics and Metabolism 100, no. 3 (2010): 283–291.

[121] B. Taurbekova, K. Mukhtarova, Z. Salpynov, K. Atageldiyeva, and A. Sarria-Santamera, “The Impact of PPARγ and ApoE Gene Polymorphisms on Susceptibility to Diabetic Kidney Disease in Type 2 Diabetes Mellitus: A Meta-analysis,” BMC Nephrology 25, no. 1 (2024): 436.

[122] L. Wu, Y. Zhang, H. Zhao, et al., “Dissecting the Association of Apolipoprotein E Gene Polymorphisms with Type 2 Diabetes Mellitus and Coronary Artery Disease,” Front Endocrinol (Lausanne) 13 (2022): 838547.

[123] P. Rajkarnikar, A. Bhattarai, K. C. Shanker, C. Monastiriotis, and Y. C. Xu, “Association Between Apolipoprotein E (APOE) Gene and Diabetic Peripheral Neuropathy: A Meta-analysis,” Sri Lanka Journal of Diabetes Endocrinology and Metabolism 8, no. 2 (2018): 3–12.

[124] M. J. Yousefzadeh, R. R. Flores, Y. Zhu, et al., “An Aged Immune System Drives Senescence and Ageing of Solid Organs,” Nature 594, no. 7861 (2021): 100–105.

[125] N. Herranz and J. Gil, “Mechanisms and Functions of Cellular Senescence,” Journal of Clinical Investigation 128, no. 4 (2018): 1238–1246.

[126] M. Collado, M. Blasco, and M. Serrano, “Cellular Senescence in Cancer and Aging,” Cell 130, no. 2 (2007): 223–233.

[127] J. Campisi, “Aging, Cellular Senescence, and Cancer,” Annual Review of Physiology 75 (2013): 685–705.

[128] J. Coppé, P. Y. Desprez, A. Krtolica, and J. Campisi, “The Senescence-associated Secretory Phenotype: The Dark Side of Tumor Suppression,” Annu Rev Pathol 5 (2010): 99–118.

[129] S. Khosla, J. N. Farr, T. Tchkonia, and J. L. Kirkland, “The Role of Cellular Senescence in Ageing and Endocrine Disease,” Nature reviews Endocrinology 16, no. 5 (2020): 263–275.

[130] E. Csekes and L. Račková, “Skin Aging, Cellular Senescence and Natural Polyphenols,” International Journal of Molecular Sciences 22, no. 23 (2021): 12641.

[131] S. Saez-Atienzar and E. Masliah, “Cellular Senescence and Alzheimer Disease: The Egg and the Chicken Scenario,” Nature Reviews Neuroscience 21, no. 8 (2020): 433–444.

[132] D. Baker and R. Petersen, “Cellular Senescence in Brain Aging and Neurodegenerative Diseases: Evidence and Perspectives,” Journal of Clinical Investigation 128, no. 4 (2018): 1208–1216.

[133] P. Zhang, Y. Kishimoto, I. Grammatikakis, et al., “Senolytic Therapy Alleviates Aβ-associated Oligodendrocyte Progenitor Cell Senescence and Cognitive Deficits in an Alzheimer's Disease Model,” Nature Neuroscience 22, no. 5 (2019): 719–728.

[134] J. R. Herdy, L. Traxler, R. K. Agarwal, et al., “Increased Post-mitotic Senescence in Aged human Neurons Is a Pathological Feature of Alzheimer's Disease,” Cell Stem Cell 29, no. 12 (2022): 1637–1652.e6.

[135] J. Cohen and C. Torres, “Astrocyte Senescence: Evidence and Significance,” Aging Cell 18, no. 3 (2019): e12937.

[136] C. Kuehnemann and C. Wiley, “Cholesterol Drives Inflammatory Senescence,” Nat Metab 5, no. 3 (2023): 355–356.

[137] K. Roh, J. Noh, Y. Kim, et al., “Lysosomal Control of Senescence and Inflammation Through Cholesterol Partitioning,” Nat Metab 5, no. 3 (2023): 398–413.

[138] S. Wang, B. Li, J. Li, et al., “Cellular Senescence Induced by Cholesterol Accumulation Is Mediated by Lysosomal ABCA1 in APOE4 and AD,” Mol Neurodegener 20, no. 1 (2025): 15.

[139] H. Zhao, Q. Ji, Z. Wu, et al., “Destabilizing Heterochromatin by APOE Mediates Senescence,” Nat Aging 2, no. 4 (2022): 303–316.

[140] S. Lv, Y. Zhang, Y. Lin, et al., “ApoE4 exacerbates the Senescence of Hippocampal Neurons and Spatial Cognitive Impairment by Downregulating Acetyl-CoA Level,” Aging Cell 22, no. 9 (2023): e13932.

[141] T. Demby, P. S. Gross, J. Mandelblatt, J. K. Huang, and G. W. Rebeck, “The Chemotherapeutic Agent Doxorubicin Induces Brain Senescence, With Modulation by APOE Genotype,” Experimental Neurology 371 (2024): 114609.

[142] N. Bancaro, B. Calì, M. Troiani, et al., “Apolipoprotein E Induces Pathogenic Senescent-Like Myeloid Cells in Prostate Cancer,” Cancer Cell 41, no. 3 (2023): 602–619.e11.

[143] Y. Hashimoto, H. Jiang, T. Niikura, et al., “Neuronal Apoptosis by Apolipoprotein E4 Through Low-density Lipoprotein Receptor-related Protein and Heterotrimeric GTPases,” Journal of Neuroscience 20, no. 22 (2000): 8401–8409.

[144] H. Wang, H. Zhou, R. Ren, S. Du, Z. Guo, and X. Shen, “Apolipoprotein E2 Inhibits Mitochondrial Apoptosis in Pancreatic Cancer Cells Through ERK1/2/CREB/BCL-2 Signaling,” Hepatobiliary & Pancreatic Diseases International 22, no. 2 (2023): 179–189.

[145] L. Atehortua, J. Morris, S. E. Street, N. Bedel, W. S. Davidson, and C. A. Chougnet, “Apolipoprotein E-containing HDL Decreases Caspase-dependent Apoptosis of Memory Regulatory T Lymphocytes,” Journal of Lipid Research 64, no. 9 (2023): 100425.

[146] F. Nardi, R. Del Prete, R. Drago, et al., “Apoliprotein E-mediated Ferroptosis Controls Cellular Proliferation in Chronic Lymphocytic Leukemia,” Leukemia 39, no. 1 (2025): 122–133.

[147] A. A. Belaidi, S. Masaldan, A. Southon, et al., “Apolipoprotein E Potently Inhibits Ferroptosis by Blocking Ferritinophagy,” Molecular Psychiatry 29, no. 2 (2024): 211–220.

[148] R. M. DeKroon, M. Mihovilovic, Z. V. Goodger, et al., “ApoE Genotype-specific Inhibition of Apoptosis,” Journal of Lipid Research 44, no. 8 (2003): 1566–1573.

[149] Z. Ji, R. D. Miranda, Y. M. Newhouse, K. H. Weisgraber, Y. Huang, and R. W. Mahley, “Apolipoprotein E4 Potentiates Amyloid Beta Peptide-induced Lysosomal Leakage and Apoptosis in Neuronal Cells,” Journal of Biological Chemistry 277, no. 24 (2002): 21821–21828.

[150] A. Brooks-Wilson, “Genetics of Healthy Aging and Longevity,” Human Genetics 132, no. 12 (2013): 1323–1338.

[151] R. Holmes, H. Duan, O. Bagley, et al., “How Are APOE4, Changes in Body Weight, and Longevity Related? Insights From a Causal Mediation Analysis,” Front Aging 5 (2024): 1359202.

[152] A. M. Kulminski, Y. Loika, I. Culminskaya, et al., “Independent Associations of TOMM40 and APOE Variants With Body Mass Index,” Aging Cell 18, no. 1 (2019): e12869.

[153] P. Sebastiani, A. Gurinovich, M. Nygaard, et al., “APOE Alleles and Extreme Human Longevity,” Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 74, no. 1 (2019): 44–51.

[154] A. Santovito, G. Galli, and S. Ruberto, “Evaluation of the Possible Association of Body Mass Index and Four Metabolic Gene Polymorphisms With Longevity in an Italian Cohort: A Role for APOE, eNOS and FTO Gene Polymorphisms,” Annals of Human Biology 46, no. 5 (2019): 425–429.

[155] P. Abondio, M. Sazzini, P. Garagnani, et al., “The Genetic Variability of APOE in Different Human Populations and Its Implications for Longevity,” Genes (Basel) 10, no. 3 (2019): 222.

[156] O. Ajnakina, D. Shamsutdinova, D. Stahl, and A. Steptoe, “Polygenic Propensity for Longevity, APOE-ε4 Status, Dementia Diagnosis, and Risk for Cause-Specific Mortality: A Large Population-Based Longitudinal Study of Older Adults,” The Journals of Gerontology: Series A 78, no. 11 (2023): 1973–1982.

[157] J. Smith, “Apolipoproteins and Aging: Emerging Mechanisms,” Ageing Research Reviews 1, no. 3 (2002): 345–365.

[158] P. Sebastiani, Z. Song, D. Ellis, et al., “A Metabolomic Signature of the APOE2 Allele,” Geroscience 45, no. 1 (2023): 415–426.

[159] J. FENG, L. XIANG, G. WAN, et al., “Is APOE ε3 a Favourable Factor for the Longevity: An Association Study in Chinese Population,” Journal of Genetics 90, no. 2 (2011): 343–347.

[160] T. Williams, T. Bathe, Q. Vo, et al., “Humanized APOE Genotypes Influence Lifespan Independently of Tau Aggregation in the P301S Mouse Model of Tauopathy,” Acta Neuropathologica Communications 11, no. 1 (2023): 99.

[161] Y. Shi, K. Yamada, S. A. Liddelow, et al., “ApoE4 markedly Exacerbates Tau-mediated Neurodegeneration in a Mouse Model of Tauopathy,” Nature 549, no. 7673 (2017): 523–527.

[162] M. Shinohara, K. Suzuki, G. Bu, and N. Sato, “Interaction between APOE Genotype and Diabetes in Longevity,” Journal of Alzheimer's Disease 82, no. 2 (2021): 719–726.

[163] M. Shinohara, T. Kanekiyo, M. Tachibana, et al., “APOE2 is Associated With Longevity Independent of Alzheimer's Disease,” Elife 9 (2020): e62199.

[164] M. T. Tejedor, M. P. Garcia-Sobreviela, M. Ledesma, and J. M. Arbones-Mainar, “The Apolipoprotein E Polymorphism rs7412 Associates With Body Fatness Independently of Plasma Lipids in Middle Aged Men,” PLoS ONE 9, no. 9 (2014): e108605.

[165] K. A. Volcik, R. A. Barkley, R. G. Hutchinson, et al., “Apolipoprotein E Polymorphisms Predict Low Density Lipoprotein Cholesterol Levels and Carotid Artery Wall Thickness but Not Incident Coronary Heart Disease in 12,491 ARIC Study Participants,” American Journal of Epidemiology 164, no. 4 (2006): 342–348.

[166] K. K. Alharbi, R. Syed, F. K. Alharbi, and I. A. Khan, “Association of Apolipoprotein E Polymorphism With Impact on Overweight University Pupils,” Genet Test Mol Biomarkers 21, no. 1 (2017): 53–57.

[167] J. A. Ellis, A. Ponsonby, A. Pezic, et al., “APOE Genotype and Cardio-respiratory Fitness Interact to Determine Adiposity in 8-year-old Children From the Tasmanian Infant Health Survey,” PLoS ONE 6, no. 11 (2011): e26679.

[168] J. M. Arbones-Mainar, L. A. Johnson, E. Torres-Perez, et al., “Metabolic Shifts Toward Fatty-acid Usage and Increased Thermogenesis Are Associated With Impaired Adipogenesis in Mice Expressing human APOE4,” International Journal of Obesity (Lond) 40, no. 10 (2016): 1574–1581.

[169] L. P. Franco, A. Gonçalves Zardini Silveira, R. Sobral de Assis Vasconcelos Lima, M. A. Horst, and C. Cominetti, “APOE Genotype Associates With Food Consumption and Body Composition to Predict Dyslipidaemia in Brazilian Adults With Normal-weight Obesity Syndrome,” Clinical Nutrition 37, no. 5 (2018): 1722–1727.

[170] I. H. Choi, S. Wang, Y. H. Um, H. K. Lim, C. U. Lee, and D. W. Kang, “Higher Fat-Related Body Composition Measurement and Lower Resting-State Inter-Network Functional Connectivity of APOE ε4 Carrier in Mild Cognitive Impairment Patients with Aβ Deposition,” Psychiatry Investig 20, no. 12 (2023): 1177–1184.

[171] T. Ando, K. Uchida, T. Sugimoto, et al., “ApoE4 Is Associated with Lower Body Mass, Particularly Fat Mass, in Older Women with Cognitive Impairment,” Nutrients 14, no. 3 (2022): 539.

[172] A. Smith, J. E. Keller, M. K. Taylor, J. M. Burns, and D. K. Sullivan, “APOE4 Genotype Relates With Body Mass and Percent Fat Mass in Cognitively Normal Older Adults,” Alzheimer's & Dementia 19 (2023): e080517.

[173] C. Jiang and F. Lin, “Insights Into the Roles of Apolipoprotein E in Adipocyte Biology and Obesity,” Int J Obes (Lond) 48, no. 9 (2024): 1205–1215.

[174] R. O. Alvim, S. R. Freitas, N. E. Ferreira, et al., “APOE Polymorphism Is Associated With Lipid Profile, but Not With Arterial Stiffness in the General Population,” Lipids Health Dis 9 (2010): 128.

[175] K. Alharbi, I. Khan, and R. Syed, “Association of Apolipoprotein E Polymorphism With Type 2 Diabetes Mellitus in a Saudi Population,” Dna and Cell Biology 33, no. 9 (2014): 637–641.

[176] N. Hassan, S. A. El-Masry, W. A. Zarouk, A. I. Abd Elneam, E. Abdel Rasheed, and M. M. Mahmoud, “Apo Lipoprotein E Polymorphism as Risk Factor for Lipid Profile Disturbance Among Obese Egyptian Females,” Research Journal of Pharmaceutical, Biological and Chemical Sciences 7, no. 2 (2016): 1826–1833.

[177] Y. Sun, R. Wei, D. Yan, et al., “Association Between APOE Polymorphism and Metabolic Syndrome in Uyghur Ethnic Men,” BMJ Open 6, no. 1 (2016): e010049.

[178] J. Oh and E. Barrett-Connor, “Apolipoprotein E Polymorphism and Lipid Levels Differ by Gender and family History of Diabetes: The Rancho Bernardo Study,” Clinical Genetics 60, no. 2 (2001): 132–137.

[179] A. Sima, A. Iordan, and C. Stancu, “Apolipoprotein E Polymorphism a Risk Factor for Metabolic Syndrome,” Clinical Chemistry and Laboratory Medicine 45, no. 9 (2007): 1149–1153.

[180] P. Marques-Vidal, V. Bongard, J. Ruidavets, et al., “Obesity and Alcohol Modulate the Effect of Apolipoprotein E Polymorphism on Lipids and Insulin,” Obesity Research 11, no. 10 (2003): 1200–1206.

[181] J. M. Arbones-Mainar, L. A. Johnson, M. K. Altenburg, and N. Maeda, “Differential Modulation of Diet-induced Obesity and Adipocyte Functionality by human Apolipoprotein E3 and E4 in Mice,” Int J Obes (Lond) 32, no. 10 (2008): 1595–1605.

[182] D. C. Fewlass, K. Noboa, F. X. Pi-Sunyer, J. M. Johnston, S. D. Yan, and N. Tezapsidis, “Obesity-related Leptin Regulates Alzheimer's Abeta,” Faseb Journal 18, no. 15 (2004): 1870–1878.

[183] L. Shen, P. Tso, S. C. Woods, et al., “Brain Apolipoprotein E: An Important Regulator of Food Intake in Rats,” Diabetes 57, no. 8 (2008): 2092–2098.

[184] M. Flores-Dorantes, Y. Díaz-López, and R. Gutiérrez-Aguilar, “Environment and Gene Association with Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases,” Frontiers in neuroscience 14 (2020): 863.

[185] H. Zeljko, T. Škarić-Jurić, N. Narančić, et al., “E2 allele of the Apolipoprotein E Gene Polymorphism Is Predictive for Obesity Status in Roma Minority Population of Croatia,” Lipids Health Dis 10 (2011): 9.

[186] A. A. Galal, A. A. Abd Elmajeed, R. A. Elbaz, A. M. Wafa, and R. M. Elshazli, “Association of Apolipoprotein E Gene Polymorphism With the Risk of T2DM and Obesity Among Egyptian Subjects,” Gene 769 (2021): 145223.

[187] A. Bartelt, F. T. Beil, T. Schinke, et al., “Apolipoprotein E-dependent Inverse Regulation of Vertebral Bone and Adipose Tissue Mass in C57Bl/6 Mice: Modulation by Diet-induced Obesity,” Bone 47, no. 4 (2010): 736–745.

[188] S. A. Kim, S. Kweon, J. Choi, et al., “Association of APOE Genotype With Bone Mineral Density in Men and Women: The Dong-gu and Namwon Studies,” Chonnam Med J 52, no. 1 (2016): 59–63.

[189] F. Parhami, A. Garfinkel, and L. Demer, “Role of Lipids in Osteoporosis,” Arteriosclerosis, Thrombosis, and Vascular Biology 20, no. 11 (2000): 2346–2348.

[190] S. M. F. Pluijm, M. G. Dik, C. Jonker, et al., “Effects of Gender and Age on the Association of Apolipoprotein E epsilon4 With Bone Mineral Density, Bone Turnover and the Risk of Fractures in Older People,” Osteoporosis International 13, no. 9 (2002): 701–709.

[191] J. Pratt, J. Dalla Via, C. Sale, et al., “Apolipoprotein ɛ4 Is Associated with Increased Risk of Fall- and Fracture-Related Hospitalization: The Perth Longitudinal Study of Ageing Women,” Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 79, no. 8 (2024): glae134.

[192] M. Shiraki, Y. Shiraki, C. Aoki, et al., “Association of Bone Mineral Density With Apolipoprotein E Phenotype,” Journal of Bone and Mineral Research 12, no. 9 (1997): 1438–1445.

[193] M. Singh, P. Singh, S. Singh, P. K. Juneja, and T. Kaur, “A Susceptible Haplotype Within APOE Gene Influences BMD and Intensifies the Osteoporosis Risk in Postmenopausal Women of Northwest India,” Maturitas 67, no. 3 (2010): 239–244.

[194] M. Sanada, H. Nakagawa, I. Kodama, T. Sakasita, and K. Ohama, “Apolipoprotein E Phenotype Associations With Plasma Lipoproteins and Bone Mass in Postmenopausal Women,” Climacteric 1, no. 3 (1998): 188–195.

[195] M. Kohlmeier, J. Saupe, K. Schaefer, and G. Asmus, “Bone Fracture History and Prospective Bone Fracture Risk of Hemodialysis Patients Are Related to Apolipoprotein E Genotype,” Calcified Tissue International 62, no. 3 (1998): 278–281.

[196] J. Johnston, J. Cauley, and M. Ganguli, “APOE 4 and Hip Fracture Risk in a Community-based Study of Older Adults,” Journal of the American Geriatrics Society 47, no. 11 (1999): 1342–1345.

[197] J. Cauley, J. M. Zmuda, K. Yaffe, et al., “Apolipoprotein E Polymorphism: A New Genetic Marker of Hip Fracture Risk–The Study of Osteoporotic Fractures,” Journal of Bone and Mineral Research 14, no. 7 (1999): 1175–1181.

[198] K. Zajícková, I. Zofková, M. Hill, A. Horínek, and A. Nováková, “Apolipoprotein E 4 Allele Is Associated With Low Bone Density in Postmenopausal Women,” Journal of Endocrinological Investigation 26, no. 4 (2003): 312–315.

[199] I. Dick, A. Devine, A. Marangou, et al., “Apolipoprotein E4 Is Associated With Reduced Calcaneal Quantitative Ultrasound Measurements and Bone Mineral Density in Elderly Women,” Bone 31, no. 4 (2002): 497–502.

[200] S. Lee, S. Lee, and W. Yoo, “Association of Apolipoprotein E Polymorphism With Bone Mineral Density in Postmenopausal Women With Rheumatoid Arthritis,” Rheumatology (Oxford) 44, no. 8 (2005): 1067–1068.

[201] J. Seo, S. Yoon, H. H. Lim, et al., “Modulation of Bone Mineral Density and Its Response to Menopausal Hormone Therapy According to the Apolipoprotein E Genotype in Postmenopausal Korean Women,” J Menopausal Med 30, no. 1 (2024): 37–43.

[202] L. S. Souza, N. F. Rochette, D. F. Pedrosa, et al., “Role of APOE Gene in Bone Mineral Density and Incidence of Bone Fractures in Brazilian Postmenopausal Women,” Journal of Clinical Densitometry 21, no. 2 (2018): 227–235.

[203] T. Štulc, R. Češka, A. Hořínek, and J. Štěpán, “Bone Mineral Density in Patients With Apolipoprotein E Type 2/2 and 4/4 Genotype,” Physiological Research 49, no. 4 (2000): 435–439.

[204] M. W. Schoofs, M. van der Klift, A. Hofman, et al., “ApoE Gene Polymorphisms, BMD, and Fracture Risk in Elderly Men and Women: The Rotterdam Study,” Journal of Bone and Mineral Research 19, no. 9 (2004): 1490–1496.

[205] J. Richards, F. Rivadeneira, M. Inouye, et al., “Bone Mineral Density, Osteoporosis, and Osteoporotic Fractures: A Genome-wide Association Study,” Lancet 371, no. 9623 (2008): 1505–1512.

[206] U. Styrkarsdottir, B. V. Halldorsson, S. Gretarsdottir, et al., “Multiple Genetic Loci for Bone Mineral Density and Fractures,” New England Journal of Medicine 358, no. 22 (2008): 2355–2365.

[207] F. Rivadeneira, U. Styrkársdottir, K. Estrada, et al., “Twenty Bone-mineral-density Loci Identified by Large-scale Meta-analysis of Genome-wide Association Studies,” Nature Genetics 41, no. 11 (2009): 1199–1206.

[208] D. G. von Mühlen, E. Barrett-Connor, D. L. Schneider, P. A. Morin, and P. Parry, “Osteoporosis and Apolipoprotein E Genotype in Older Adults: The Rancho Bernardo Study,” Osteoporosis International 12, no. 4 (2001): 332–335.

[209] L. U. Gerdes, P. Vestergaard, A. P. Hermann, and L. Mosekilde, “Regional and Hormone-dependent Effects of Apolipoprotein E Genotype on Changes in Bone Mineral in Perimenopausal Women,” Journal of Bone and Mineral Research 16, no. 10 (2001): 1906–1916.

[210] I. Peter, M. D. Crosier, M. Yoshida, et al., “Associations of APOE Gene Polymorphisms With Bone Mineral Density and Fracture Risk: A Meta-analysis,” Osteoporosis International 22, no. 4 (2011): 1199–1209.

[211] H. M. Macdonald, F. E. McGuigan, S. A. Lanham-New, W. D. Fraser, S. H. Ralston, and D. M. Reid, “Vitamin K1 Intake Is Associated With Higher Bone Mineral Density and Reduced Bone Resorption in Early Postmenopausal Scottish Women: No Evidence of Gene-nutrient Interaction With Apolipoprotein E Polymorphisms,” American Journal of Clinical Nutrition 87, no. 5 (2008): 1513–1520.

[212] C. Ackert-Bicknell, “HDL Cholesterol and Bone Mineral Density: Is There a Genetic Link?,” Bone 50, no. 2 (2012): 525–533.

[213] Y. Wang, X. Ma, J. Guo, Y. Li, and Y. Xiong, “Correlation Between ESR1 and APOE Gene Polymorphisms and Risk of Osteonecrosis of the Femoral Head: A Case–control Study,” Journal of Orthopaedic Surgery and Research 18, no. 1 (2023): 968.

[214] P. Newman, F. Bonello, A. S. Wierzbicki, P. Lumb, G. F. Savidge, and M. J. Shearer, “The Uptake of Lipoprotein-borne Phylloquinone (vitamin K1) by Osteoblasts and Osteoblast-Like Cells: Role of Heparan Sulfate Proteoglycans and Apolipoprotein E,” Journal of Bone and Mineral Research 17, no. 3 (2002): 426–433.

[215] J. Pratt, C. Boreham, S. Ennis, A. W. Ryan, and G. De Vito, “Genetic Associations with Aging Muscle: A Systematic Review Cells,” Cells 9, no. 1 (2019): 12.

[216] A. Lejay, A. Charles, I. Georg, et al., “Critical Limb Ischaemia Exacerbates Mitochondrial Dysfunction in ApoE-/- Mice Compared With ApoE+/+ Mice, but N-acetyl Cysteine Still Confers Protection,” European Journal of Vascular and Endovascular Surgery 58, no. 4 (2019): 576–582.

[217] J. Barlow, P. P. Sfyri, R. Mitchell, et al., “Platelet Releasate Normalises the Compromised Muscle Regeneration in a Mouse Model of Hyperlipidaemia,” Experimental Physiology 106, no. 3 (2021): 700–713.

[218] B. I. Burke, J. Goh, F. A. Albathi, et al., “ApoE Isoform Does Not Influence Skeletal Muscle Regeneration in Adult Mice,” Front Physiol 14 (2023): 1302695.

[219] D. Melzer, M. G. Dik, G. J. van Kamp, C. Jonker, and D. J. Deeg, “The Apolipoprotein E e4 Polymorphism Is Strongly Associated With Poor Mobility Performance Test Results but Not Self-reported Limitation in Older People,” Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 60, no. 10 (2005): 1319–1323.

[220] I. Skoog, H. Hörder, K. Frändin, et al., “Association Between APOE Genotype and Change in Physical Function in a Population-Based Swedish Cohort of Older Individuals Followed over Four Years,” Frontiers in aging neuroscience 8 (2016): 225.

[221] J. Verghese, R. Holtzer, C. Wang, M. J. Katz, N. Barzilai, and R. B. Lipton, “Role of APOE Genotype in Gait Decline and Disability in Aging,” Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 68, no. 11 (2013): 1395–1401.

[222] Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023, Journal of the American College of Cardiology 86, no. 22 (2025): 2167–2243.

[223] H. Krishnamurthy, I. Rajavelu, S. Reddy, et al., “Association of Apolipoprotein E (APOE) Polymorphisms with Serological Lipid and Inflammatory Markers,” Cureus 16, no. 5 (2024): e60721.

[224] R. Toribio-Fernández, C. Tristão-Pereira, J. Carlos Silla-Castro, et al., “Apolipoprotein E-ε2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study,” Circulation Research 134, no. 4 (2024): 411–424.

[225] Y. Song, M. Stampfer, and S. Liu, “Meta-analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease,” Annals of Internal Medicine 141, no. 2 (2004): 137–147.

[226] W. Ma, X. Ren, L. Zhang, H. Dong, X. Lu, and W. Feng, “Apolipoprotein E Gene Polymorphism and Coronary Artery Disease Risk among Patients in Northwest China,” Pharmgenomics Pers Med 14 (2021): 1591–1599.

[227] Q. Liu, H. Wu, Z. Yu, Q. Huang, and Z. Zhong, “APOE Gene ɛ4 Allele (388C-526C) Effects on Serum Lipids and Risk of Coronary Artery Disease in Southern Chinese Hakka Population,” Journal of Clinical Laboratory Analysis 35, no. 9 (2021): e23925.

[228] D. Afroze, A. Yousuf, N. A. Tramboo, Z. A. Shah, and A. Ahmad, “ApoE Gene Polymorphism and Its Relationship With Coronary Artery Disease in Ethnic Kashmiri Population,” Clinical and Experimental Medicine 16, no. 4 (2016): 551–556.

[229] A. M. Bennet, E. Di Angelantonio, Z. Ye, et al., “Association of Apolipoprotein E Genotypes With Lipid Levels and Coronary Risk,” Jama 298, no. 11 (2007): 1300–1311.

[230] M. Eto, K. Watanabe, and K. Ishii, “Reciprocal Effects of Apolipoprotein E Alleles (epsilon 2 and epsilon 4) on Plasma Lipid Levels in Normolipidemic Subjects,” Clinical Genetics 29, no. 6 (1986): 477–484.

[231] A. Vaisi-Raygani, Z. Rahimi, H. Nomani, H. Tavilani, and T. Pourmotabbed, “The Presence of Apolipoprotein epsilon4 and epsilon2 Alleles Augments the Risk of Coronary Artery Disease in Type 2 Diabetic Patients,” Clinical Biochemistry 40, no. 15 (2007): 1150–1156.

[232] C. Koopal, M. I. Geerlings, M. Muller, et al., “The Relation Between Apolipoprotein E (APOE) Genotype and Peripheral Artery Disease in Patients at High Risk for Cardiovascular Disease,” Atherosclerosis 246 (2016): 187–192.

[233] B. Blazejewska-Hyzorek, G. Gromadzka, M. Skowronska, and A. Czlonkowska, “APOE Ε 2 Allele Is an Independent Risk Factor for Vulnerable Carotid Plaque in Ischemic Stroke Patients,” Neurological Research 36, no. 11 (2014): 950–954.

[234] Y. Long, X. Zhao, C. Liu, et al., “A Case-Control Study of the Association of the Polymorphisms of MTHFR and APOE With Risk Factors and the Severity of Coronary Artery Disease,” Cardiology 142, no. 3 (2019): 149–157.

[235] Z. Karahan, M. Uğurlu, B. Uçaman, et al., “Relation Between Apolipoprotein E Gene Polymorphism and Severity of Coronary Artery Disease in Acute Myocardial Infarction,” Cardiol Res Pract 2015 (2015): 363458.

[236] S. Ashiq and K. Ashiq, “The Association of Apolipoprotein-E (APOE) Gene Polymorphisms With Coronary Artery Disease: A Systematic Review and Meta-analysis,” Egyptian Journal of Medical Human Genetics 22, no. 1 (2021): 16.

[237] G. Wei, B. Li, H. Wang, et al., “Apolipoprotein E E3/E4 Genotype Is Associated With an Increased Risk of Coronary Atherosclerosis in Patients With Hypertension,” BMC Cardiovascular Disorders [Electronic Resource] 24, no. 1 (2024): 486.

[238] H. Xu, H. Li, J. Liu, et al., “Meta-analysis of Apolipoprotein E Gene Polymorphism and Susceptibility of Myocardial Infarction,” PLoS ONE 9, no. 8 (2014): e104608.

[239] Y. Wang, L. Sun, L. Zhang, et al., “Association Between Apolipoprotein E Polymorphism and Myocardial Infarction Risk: A Systematic Review and Meta-analysis,” FEBS Open Bio 5 (2015): 852–858.

[240] A. Shao, J. Shi, Z. Liang, et al., “Meta-analysis of the Association Between Apolipoprotein E Polymorphism and Risks of Myocardial Infarction,” BMC Cardiovascular Disorders [Electronic Resource] 22, no. 1 (2022): 126.

[241] M. W. McMaster, A. Shah, J. Kangarlu, R. Cheikhali, W. H. Frishman, and W. S. Aronow, “The Impact of the Apolipoprotein E Genotype on Cardiovascular Disease and Cognitive Disorders,” Cardiology in Review (2024).

[242] T. A. Abd El-Aziz and R. H. Mohamed, “LDLR, ApoB and ApoE Genes Polymorphisms and Classical Risk Factors in Premature Coronary Artery Disease,” Gene 590, no. 2 (2016): 263–269.

[243] S. Liu, J. Liu, R. Weng, X. Gu, and Z. Zhong, “Apolipoprotein E Gene Polymorphism and the Risk of Cardiovascular Disease and Type 2 Diabetes,” BMC Cardiovascular Disorders [Electronic Resource] 19, no. 1 (2019): 213.

[244] T. A. Khan, T. Shah, D. Prieto, et al., “Apolipoprotein E Genotype, Cardiovascular Biomarkers and Risk of Stroke: Systematic Review and Meta-analysis of 14,015 Stroke Cases and Pooled Analysis of Primary Biomarker Data From up to 60,883 Individuals,” International Journal of Epidemiology 42, no. 2 (2013): 475–492.

[245] A. V. Sorokin, N. Patel, K. M. Abdelrahman, et al., “Complex Association of Apolipoprotein E-containing HDL With Coronary Artery Disease Burden in Cardiovascular Disease,” JCI Insight 7, no. 10 (2022): e159577.

[246] K. L. Rasmussen, J. Luo, B. G. Nordestgaard, A. Tybjærg-Hansen, and R. Frikke-Schmidt, “APOE and Vascular Disease: Sequencing and Genotyping in General Population Cohorts,” Atherosclerosis 385 (2023): 117218.

[247] G. Huang, D. F. Wallace, E. E. Powell, T. Rahman, P. J. Clark, and V. N. Subramaniam, “Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics,” Biomedicines 11, no. 10 (2023): 2809.

[248] D. Lee, S. O. Lee, B. S. Mun, et al., “Relation of Apolipoprotein E Polymorphism to Clinically Diagnosed Fatty Liver Disease],” Taehan Kan Hakhoe Chi = the Korean Journal of Hepatology 8, no. 4 (2002): 355–362.

[249] M. Yang, H. J. Son, J. D. Sung, et al., “The relationship between apolipoprotein E polymorphism, lipoprotein(a) and fatty liver disease,” Hepato-Gastroenterology 52, no. 66 (2005): 1832–1835.

[250] M. D. Demirag, H. I. Onen, M. Y. Karaoguz, et al., “Apolipoprotein E Gene Polymorphism in Nonalcoholic Fatty Liver Disease,” Digestive Diseases and Sciences 52, no. 12 (2007): 3399–3403.

[251] A. Sazci, G. Akpinar, C. Aygun, E. Ergul, O. Senturk, and S. Hulagu, “Association of Apolipoprotein E Polymorphisms in Patients With Non-alcoholic Steatohepatitis,” Digestive Diseases and Sciences 53, no. 12 (2008): 3218–3224.

[252] E. De Feo, C. Cefalo, and D. Arzani, “A Case-control Study on the Effects of the Apolipoprotein E Genotypes in Nonalcoholic Fatty Liver Disease,” Molecular Biology Reports 39, no. 7 (2012): 7381–7388.

[253] S. Liu, R. Weng, X. Gu, L. Li, and Z. Zhong, “Association Between Apolipoprotein E Gene Polymorphism and Nonalcoholic Fatty Liver Disease in Southern China: A Case-control Study,” Journal of Clinical Laboratory Analysis 35, no. 12 (2021): e24061.

[254] O. Jamialahmadi, R. M. Mancina, E. Ciociola, et al., “Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated with Fatty Liver Disease,” Gastroenterology 160, no. 5 (2021): 1634–1646.e7.

[255] M. Vujkovic, S. Ramdas, K. M. Lorenz, et al., “A Multiancestry Genome-wide Association Study of Unexplained Chronic ALT Elevation as a Proxy for Nonalcoholic Fatty Liver Disease With Histological and Radiological Validation,” Nature Genetics 54, no. 6 (2022): 761–771.

[256] J. Park, M. T. MacLean, A. M. Lucas, et al., “Exome-wide Association Analysis of CT Imaging-derived Hepatic Fat in a Medical Biobank,” Cell Rep Med 3, no. 12 (2022): 100855.

[257] C. J. Fairfield, T. M. Drake, R. Pius, et al., “Genome-Wide Association Study of NAFLD Using Electronic Health Records,” Hepatol Commun 6, no. 2 (2022): 297–308.

[258] N. D. Palmer, B. Kahali, A. Kuppa, et al., “Allele-specific Variation at APOE Increases Nonalcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction,” Human Molecular Genetics 30, no. 15 (2021): 1443–1456.

[259] W. Lu, J. Mei, J. Yang, et al., “ApoE Deficiency Promotes Non-alcoholic Fatty Liver Disease in Mice via Impeding AMPK/mTOR Mediated Autophagy,” Life Sciences 252 (2020): 117601.

[260] J. C. Nascimento, G. A. Matos, L. C. Pereira, et al., “Impact of Apolipoprotein E Genetic Polymorphisms on Liver Disease: An Essential Review,” Annals of Hepatology 19, no. 1 (2020): 24–30.

[261] P. Huebbe, S. Bilke, J. Rueter, et al., “Human APOE4 Protects High-Fat and High-Sucrose Diet Fed Targeted Replacement Mice Against Fatty Liver Disease Compared to APOE3,” Aging Dis 15, no. 1 (2024): 259–281.

[262] C. Lysaker, C. N. Johnson, V. Csikos, et al., “APOE4 drives Widespread Changes to the Hepatic Proteome and Alters Metabolic Function,” BioRxiv 29, no. 3 (2025): 115035.

[263] S. von Hardenberg, C. Gnewuch, G. Schmitz, and J. Borlak, “ApoE Is a Major Determinant of Hepatic Bile Acid Homeostasis in Mice,” The Journal of Nutritional Biochemistry 52 (2018): 82–91.

[264] D. Tian, S. Jiang, Y. Liu, et al., “Causal Association of Cholesterol Metabolism-related Proteins With Hepatocellular Carcinoma and Dysfunction-associated Steatotic Liver Disease: A Mendelian Randomization Study,” Discov Oncol 16, no. 1 (2025): 987.

[265] K. L. Rasmussen, A. Tybjærg-Hansen, B. G. Nordestgaard, and R. Frikke-Schmidt, “APOE and Dementia—resequencing and Genotyping in 105,597 Individuals,” Alzheimers Dement 16, no. 12 (2020): 1624–1637.

[266] W. Lee, S. H. Choi, M. G. Shea, et al., “Association of Common and Rare Variants With Alzheimer's Disease in More Than 13,000 Diverse Individuals With Whole-genome Sequencing From the Alzheimer's Disease Sequencing Project,” Alzheimers Dement 20, no. 12 (2024): 8470–8483.

[267] M. M. Aslam, K. Fan, E. Lawrence, et al., “Genome-wide Analysis Identifies Novel Loci Influencing Plasma Apolipoprotein E Concentration and Alzheimer's Disease Risk,” Molecular Psychiatry 28, no. 10 (2023): 4451–4462.

[268] Y. Ma, G. R. Jun, X. Zhang, et al., “Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype,” JAMA neurology 76, no. 9 (2019): 1099–1108.

[269] Y. Le Guen, M. E. Belloy, B. Grenier-Boley, et al., “Association of Rare APOE Missense Variants V236E and R251g with Risk of Alzheimer Disease,” JAMA Neurology 79, no. 7 (2022): 652–663.

[270] H. Yassine, I. Arellanes, A. Mazmanian, et al., “Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers Before the Onset of Dementia,” The Journal of Prevention of Alzheimer's Disease 10, no. 4 (2023): 810–820.

[271] E. A. Liehn, V. Ponomariov, R. Diaconu, et al., “Apolipoprotein E in Cardiovascular Diseases: Novel Aspects of an Old-fashioned Enigma,” Archives of Medical Research 49, no. 8 (2018): 522–529.

[272] C. Hsu, T. Hsu, Y. Kao, et al., “The Efficacy and Safety of Anti-amyloid Monoclonal Antibody versus Acetylcholinesterase Inhibitor With an in-depth Analysis Across Genotypes and Disease Stages: A Systematic Review and Meta-analysis,” J Prev Alzheimers Dis 12, no. 8 (2025): 100195.

[273] I. G. Asiimwe, T. Gebru, A. L. Jorgensen, and M. Pirmohamed, Multimorbidity Mechanism and Therapeutics Research Collaborative, “APOE Genotype and the Effect of Statins: A Systematic Review and Meta-analysis,” medRxiv (2024), 2024.12.13.24318973.

[274] Y. Wang, X. Du, R. Zhao, J. Niu, H. Wang, and J. Li, “Association of APOE Polymorphisms With Lipid-lowering Efficacy of Statins in Atherosclerotic Cardiovascular Diseases,” Ann Acad Med Singap 50, no. 6 (2021): 474–480.

[275] J. Poblano, I. Castillo-Tobías, L. Berlanga, et al., “Drugs Targeting APOE4 That Regulate Beta-amyloid Aggregation in the Brain: Therapeutic Potential for Alzheimer's Disease,” Basic & Clinical Pharmacology & Toxicology 135, no. 3 (2024): 237–249.

[276] A. Litvinchuk, T. V. Huynh, Y. Shi, et al., “Apolipoprotein E4 Reduction With Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model,” Annals of Neurology 89, no. 5 (2021): 952–966.

[277] A. Yang, B. Kantor, and O. Chiba-Falek, “APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's,” International Journal of Molecular Sciences 22, no. 3 (2021): 1244.

[278] L. Vandermeulen, I. Geric, L. Fumagalli, et al., “Regulation of human Microglial Gene Expression and Function via RNAase-H Active Antisense Oligonucleotides in Vivo in Alzheimer's Disease,” Mol Neurodegener 19, no. 1 (2024): 37.

[279] Y. Li, J. R. Macyczko, C. Liu, and G. Bu, “ApoE4 reduction: An Emerging and Promising Therapeutic Strategy for Alzheimer's Disease,” Neurobiology of Aging 115 (2022): 20–28.

[280] F. L. Vecchio, P. Bisceglia, B. P. Imbimbo, et al., “Are Apolipoprotein E Fragments a Promising New Therapeutic Target for Alzheimer's Disease?,” Ther Adv Chronic Dis 13 (2022): 20406223221081605.

[281] D. J. Christensen, N. Ohkubo, J. Oddo, et al., “Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A,” Journal of Immunology 186, no. 4 (2011): 2535–2542.

[282] M. Safieh, A. Korczyn, and D. Michaelson, “ApoE4: An Emerging Therapeutic Target for Alzheimer's Disease,” BMC Medicine [Electronic Resource] 17, no. 1 (2019): 64.

[283] S. Ahmed, A. Pande, and S. Sharma, “Therapeutic Potential of ApoE-mimetic Peptides in CNS Disorders: Current Perspective,” Experimental Neurology 353 (2022): 114051.

[284] K. Krishnamurthy, V. Cantillana, H. Wang, et al., “ApoE Mimetic Improves Pathology and Memory in a Model of Alzheimer's Disease,” Brain Research 1733 (2020): 146685.

[285] J. T. Guptill, S. M. Raja, F. Boakye-Agyeman, et al., “Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects,” Journal of Clinical Pharmacology 57, no. 6 (2017): 770–776.

[286] S. Li, R. Wangqin, X. Meng, et al., “Tolerability and Pharmacokinetics of Single Escalating and Repeated Doses of CN-105 in Healthy Participants,” Clinical Therapeutics 44, no. 5 (2022): 744–754.

[287] M. L. James, J. Troy, N. Nowacki, et al., “CN-105 in Participants With Acute Supratentorial Intracerebral Hemorrhage (CATCH) Trial,” Neurocrit Care 36, no. 1 (2022): 216–225.

[288] A. M. Petros, A. Korepanova, C. G. Jakob, et al., “Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer,” Journal of Medicinal Chemistry 62, no. 8 (2019): 4120–4130.

[289] C. Wang, R. Najm, Q. Xu, et al., “Gain of Toxic Apolipoprotein E4 Effects in human iPSC-derived Neurons Is Ameliorated by a Small-molecule Structure Corrector,” Nature Medicine 24, no. 5 (2018): 647–657.

[290] T. Williams, D. Borchelt, and P. Chakrabarty, “Therapeutic Approaches Targeting Apolipoprotein E Function in Alzheimer's Disease,” Mol Neurodegener 15, no. 1 (2020): 8.

[291] A. Wolska, M. Reimund, D. O. Sviridov, M. J. Amar, and A. T. Remaley, “Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases,” Cells 10 (2021): 597, https://doi.org/10.3390/cells10030597.

[292] G. Datta, M. Chaddha, D. W. Garber, et al., “The Receptor Binding Domain of Apolipoprotein E, Linked to a Model Class A Amphipathic Helix, Enhances Internalization and Degradation of LDL by Fibroblasts,” Biochemistry 39, no. 1 (2000): 213–220.

[293] Q. Xie, F. Li, and S. Zhao, “Ac‑hE‑18A‑NH2, a novel dual‑domain apolipoprotein mimetic peptide, inhibits apoptosis in macrophages by promoting cholesterol efflux,” Mol Med Rep 9, no. 5 (2014): 1851–1856.

[294] S. S. Minami, A. Cordova, J. R. Cirrito, et al., “ApoE Mimetic Peptide Decreases Abeta Production in Vitro and in Vivo,” Mol Neurodegener 5 (2010): 16.

[295] B. P. Meloni, D. J. Blacker, F. L. Mastaglia, and N. W. Knuckey, “Emerging Cytoprotective Peptide Therapies for Stroke,” Expert Review of Neurotherapeutics 20, no. 9 (2020): 887–890.

[296] T. M. Tu, B. J. Kolls, E. J. Soderblom, et al., “Apolipoprotein E Mimetic Peptide, CN-105, Improves Outcomes in Ischemic Stroke,” Ann Clin Transl Neurol 4, no. 4 (2017): 246–265.

[297] B. Lei, M. L. James, J. Liu, et al., “Neuroprotective Pentapeptide CN-105 Improves Functional and Histological Outcomes in a Murine Model of Intracerebral Hemorrhage,” Scientific Reports 6, no. 1 (2016): 34834.

[298] M. Xue, S. Li, M. Xu, et al., “Antagonism of Nicotinic Acetycholinergic Receptors by CN-105, an apoE-mimetic Peptide Reduces Stroke-induced Excitotoxicity,” Clinical and translational medicine 12, no. 1 (2022): e677.

[299] F. Liao, L. Aimin, M. Xiong, et al., “Targeting of Nonlipidated, Aggregated apoE With Antibodies Inhibits Amyloid Accumulation,” Journal of Clinical Investigation 128, no. 5 (2018): 2144–2155.

[300] M. Xiong, H. Jiang, J. R. Serrano, et al., “APOE Immunotherapy Reduces Cerebral Amyloid Angiopathy and Amyloid Plaques While Improving Cerebrovascular Function,” Science Translational Medicine 13, no. 581 (2021): eabd7522.

[301] H. Chen, Z. Liu, A. Meyer-Franke, et al., “Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons,” Journal of Biological Chemistry 287, no. 8 (2012): 5253–5266.

[302] H. N. Yassine, C. Hugo, B. O'Donovan, et al., “APOE-Targeted Therapeutics for Alzheimer's Disease,” Journal of Neuroscience 45, no. 46 (2025): e1388252025.

[303] A. Belaidi, A. Bush, and S. Ayton, “Apolipoprotein E in Alzheimer's Disease: Molecular Insights and Therapeutic Opportunities,” Molecular Neurodegeneration 20, no. 1 (2025): 47.

[304] J. Kutzsche, D. Jürgens, A. Willuweit, et al., “Safety and Pharmacokinetics of the Orally Available Antiprionic Compound PRI-002: A Single and Multiple Ascending Dose Phase I Study,” Alzheimers Dement (N Y) 6, no. 1 (2020): e12001.

[305] J. Kutzsche, N. C. Cosma, G. Kauselmann, et al., “Oral PRI-002 Treatment in Patients With MCI or Mild AD: A Randomized, Double-blind Phase 1b Trial,” Nature Communications 16, no. 1 (2025): 4180.

[306] B. György, C. Lööv, M. P. Zaborowski, et al., “CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease,” Mol Ther Nucleic Acids 11 (2018): 429–440.

[307] Y. Lin, J. Seo, F. Gao, et al., “APOE4 causes Widespread Molecular and Cellular Alterations Associated With Alzheimer's Disease Phenotypes in human iPSC-derived Brain Cell Types,” Neuron 98 (2018): 1141–1154.

[308] I. Asiimwe, A. Jorgensen, and M. Pirmohamed, “APOE Genotype and Statin Response: Evidence from the UK Biobank and All of Us Program,” Clin Transl Sci 18, no. 8 (2025): e70314.

[309] L. Zhang, S. He, Z. Li, et al., “Apolipoprotein E Polymorphisms Contribute to Statin Response in Chinese ASCVD Patients With Dyslipidemia,” Lipids Health Dis 18, no. 1 (2019): 129.

[310] S. Liang, L. M. Steffen, B. T. Steffen, et al., “APOE Genotype Modifies the Association Between Plasma Omega-3 Fatty Acids and Plasma Lipids in the Multi-Ethnic Study of Atherosclerosis (MESA),” Atherosclerosis 228, no. 1 (2013): 181–187.

[311] J. Hey, J. Y. Yu, S. Abushakra, et al., “Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers With Early Alzheimer's Disease,” Clinical Pharmacokinetics 64, no. 3 (2025): 407–424.

[312] J. A. Hey, J. Y. Yu, S. Abushakra, et al., “Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition From a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers With Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model,” Drugs 84, no. 7 (2024): 825–839.

[313] J. A. Hey, S. Abushakra, K. Blennow, et al., “Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers With Early Alzheimer's Disease,” Drugs 84, no. 7 (2024): 811–823.

[314] S. Abushakra, A. Power, D. Watson, et al., “Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes With Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial,” Drugs 85, no. 11 (2025): 1455–1472.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.